AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21751879 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid-antibiotic combination (betamethasone 0.1%-sulfacetamide sodium 10%)
Number of subjects: 20
Study 19733608 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent thinking training program
Number of subjects: 17
Study 19733608 — intervention group
Group type: COMPARATOR
Intervention: Control program on convergent thinking
Number of subjects: 17
Study 17513628 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat dose of ondansetron 4 mg
Number of subjects: 88
Study 17513628 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 88
Study 17513628 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 88
Study 15118190 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte (CHO) solution
Number of subjects: 8
Study 15118190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) solution
Number of subjects: 8
Study 11451122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tapered pins
Number of subjects: 0
Study 11451122 — intervention group
Group type: COMPARATOR
Intervention: Standard tapered pins
Number of subjects: 0
Study 9526460 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented student feedback (norm-referenced, graphic summaries and individualized teaching-effectiveness guidelines)
Number of subjects: 81
Study 9526460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no augmented feedback)
Number of subjects: 81
Study 9526460 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with medium or high baseline scores
Number of subjects: 81
Study 9526460 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with low baseline scores
Number of subjects: 81
Study 7805634 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS-prevention group
Number of subjects: 206
Study 7805634 — intervention group
Group type: COMPARATOR
Intervention: Health-promotion group
Number of subjects: 206
Study 7805634 — intervention group
Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 206
Study 3182111 — intervention group
Group type: EXPERIMENTAL
Intervention: May and Baker preparation of metronidazole (200 mg)
Number of subjects: 8
Study 3182111 — intervention group
Group type: COMPARATOR
Intervention: Servipharm preparation of metronidazole (200 mg)
Number of subjects: 8
Study 3182111 — intervention group
Group type: EXPERIMENTAL
Intervention: May and Baker preparation of metronidazole
Number of subjects: 8
Study 3182111 — intervention group
Group type: COMPARATOR
Intervention: Servipharm preparation of metronidazole
Number of subjects: 8
Study 30374191 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/samidorphan (BUP/SAM) 2 mg/2 mg
Number of subjects: 0
Study 30374191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30958334 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality exercise program (Nintendo Wii Fit Plus), 10 minutes of strength and 10 minutes of balance exercises
Number of subjects: 21
Study 30958334 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program (TheraBand), 10 minutes of ankle strength exercises and 10 minutes of balance exercises
Number of subjects: 21
Study 28284167 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 0
Study 26041677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phytate (HP) diet
Number of subjects: 32
Study 26041677 — intervention group
Group type: COMPARATOR
Intervention: Low-phytate (LP) diet
Number of subjects: 32
Study 23704060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress MR imaging (DS‐MR) at 10 μg/kg/min and 20 μg/kg/min
Number of subjects: 18
Study 23704060 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stress MR imaging (DS‐MR) in normal volunteers
Number of subjects: 18
Study 22833195 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7600563 (genetic variant)
Number of subjects: 7860
Study 19005170 — intervention group
Group type: COMPARATOR
Intervention: SIENA
Number of subjects: 43
Study 19005170 — intervention group
Group type: COMPARATOR
Intervention: CCV
Number of subjects: 43
Study 19005170 — intervention group
Group type: COMPARATOR
Intervention: SIENAX
Number of subjects: 43
Study 17990453 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with compound Reinhartdt and Sea Cumber Capsule (RSC) and Donepezil
Number of subjects: 63
Study 17990453 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63
Study 17990453 — intervention group
Group type: COMPARATOR
Intervention: RSC
Number of subjects: 63
Study 16359481 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylvinylether‐maleic anhydride (PVM‐MA) adhesive paste
Number of subjects: 30
Study 16359481 — intervention group
Group type: COMPARATOR
Intervention: Carboxymethyl cellulose (CC) adhesive paste
Number of subjects: 30
Study 16359481 — intervention group
Group type: COMPARATOR
Intervention: Retention of maxillary dentures
Number of subjects: 30
Study 16359481 — intervention group
Group type: COMPARATOR
Intervention: Taste
Number of subjects: 30
Study 16359481 — intervention group
Group type: COMPARATOR
Intervention: Removal of the adhesive
Number of subjects: 30
Study 11756370 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete time Markov chain analysis
Number of subjects: 0
Study 11756370 — intervention group
Group type: COMPARATOR
Intervention: Standard analyses
Number of subjects: 0
Study 9820719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow-rate (LFR) group with 2.5 L/min insufflation
Number of subjects: 76
Study 9820719 — intervention group
Group type: COMPARATOR
Intervention: High flow-rate (HFR) group with 7.5 L/min insufflation
Number of subjects: 76
Study 9820719 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time for LFR
Number of subjects: 76
Study 9820719 — intervention group
Group type: COMPARATOR
Intervention: Operation time for HFR
Number of subjects: 76
Study 7641736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with RDI > median value
Number of subjects: 43
Study 7641736 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide with RDI < median value
Number of subjects: 43
Study 7641736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with RDI > median value
Number of subjects: 43
Study 7641736 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with RDI < median value
Number of subjects: 43
Study 7641736 — intervention group
Group type: EXPERIMENTAL
Intervention: CP regimen with ARDI > median value
Number of subjects: 43
Study 7641736 — intervention group
Group type: COMPARATOR
Intervention: CP regimen with ARDI < median value
Number of subjects: 43
Study 2655685 — intervention group
Group type: EXPERIMENTAL
Intervention: zofenopril
Number of subjects: 38
Study 2655685 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 38
Study 336057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumon Gel (etofenamate)
Number of subjects: 69
Study 336057 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 69
Study 30375187 — intervention group
Group type: EXPERIMENTAL
Intervention: O-R electric toothbrush with novel round brush head (EB60) on an Oral-B Vitality O-R handle (D12)
Number of subjects: 150
Study 30375187 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (ADA manual toothbrush)
Number of subjects: 150
Study 28193616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks
Number of subjects: 34
Study 28193616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25297572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.5 mg) tablets twice daily
Number of subjects: 19
Study 25297572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23582525 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based HIV educational video (102 participants)
Number of subjects: 203
Study 23582525 — intervention group
Group type: COMPARATOR
Intervention: In-person HIV counseling session (101 participants)
Number of subjects: 203
Study 21481651 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak 1 NFR (single ascending series of stimulations)
Number of subjects: 0
Study 21481651 — intervention group
Group type: COMPARATOR
Intervention: Staircase NFR (3 ascending/descending staircases of stimulations)
Number of subjects: 0
Study 19092650 — intervention group
Group type: EXPERIMENTAL
Intervention: Every other day hemodialysis (eodHD)
Number of subjects: 18
Study 19092650 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (cHD)
Number of subjects: 18
Study 17053552 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg once daily
Number of subjects: 59
Study 17053552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2 microg) administered intravenously
Number of subjects: 16
Study 15525445 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam administered to achieve steady state
Number of subjects: 16
Study 15525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (2 microg) administered intravenously
Number of subjects: 16
Study 10443770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 600 microg/kg/hr
Number of subjects: 40
Study 10443770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7529467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (3.8 x 10(6) Kallikrein inactivation units)
Number of subjects: 53
Study 7529467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7529467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 53
Study 2192099 — intervention group
Group type: EXPERIMENTAL
Intervention: Abana (800 mg tds)
Number of subjects: 43
Study 2192099 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (M-DOPA, 250 mg tds)
Number of subjects: 43
Study 457528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole premedication after 3 days
Number of subjects: 16
Study 457528 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication after 3 days
Number of subjects: 16
Study 457528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at high altitude
Number of subjects: 16
Study 31781694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) gel applied topically on the day of frenectomy and on days 3, 7, and 14 postoperatively
Number of subjects: 40
Study 31781694 — intervention group
Group type: COMPARATOR
Intervention: No application of HA gel (Control)
Number of subjects: 40
Study 31690647 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT) consisting of seven weekly modules with support from a web therapist.
Number of subjects: 0
Study 31690647 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) with no constraints regarding the range of treatments.
Number of subjects: 0
Study 28844200 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open face mask)
Number of subjects: 6629
Study 28844200 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 6629
Study 28844200 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 6629
Study 24220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day (oral) in repeated cycles of 4-week on/2-week off schedule
Number of subjects: 750
Study 24220935 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α (IFN-α) 9 million units subcutaneously thrice weekly
Number of subjects: 750
Study 22523198 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 643
Study 22523198 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 643
Study 19066303 — intervention group
Group type: EXPERIMENTAL
Intervention: GH bolus administered postabsorptively
Number of subjects: 10
Study 19066303 — intervention group
Group type: EXPERIMENTAL
Intervention: GH bolus administered in the fasting state (37.5 h)
Number of subjects: 10
Study 17469890 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week hypnotic taper program with self-help CBT
Number of subjects: 53
Study 17469890 — intervention group
Group type: COMPARATOR
Intervention: 8-week hypnotic taper program alone
Number of subjects: 53
Study 16045027 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage administration sedation method (with propofol plus midazolam)
Number of subjects: 64
Study 16045027 — intervention group
Group type: COMPARATOR
Intervention: Routine continuum administration sedation method
Number of subjects: 64
Study 12216337 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin (COC with drospirenone and ethinylestradiol)
Number of subjects: 0
Study 12216337 — intervention group
Group type: COMPARATOR
Intervention: Other COCs
Number of subjects: 0
Study 9457025 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliances
Number of subjects: 36
Study 9457025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h
Number of subjects: 12
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h
Number of subjects: 12
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Number of subjects: 12
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Number of subjects: 12
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Number of subjects: 12
Study 8585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ciprofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Number of subjects: 12
Study 2376426 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (200 mg ibuprofen)
Number of subjects: 10
Study 2376426 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (200 mg ibuprofen)
Number of subjects: 10
Study 2376426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 10
Study 6158257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide 370 mg I/ml)
Number of subjects: 52
Study 6158257 — intervention group
Group type: COMPARATOR
Intervention: Isopaque Coronar (metrizoate 370 mg I/ml)
Number of subjects: 52
Study 30905265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) as part of the IAPT initiative
Number of subjects: 0
Study 28599676 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN + EN
Number of subjects: 125
Study 28599676 — intervention group
Group type: COMPARATOR
Intervention: EN alone
Number of subjects: 125
Study 25923462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPre)
Number of subjects: 40
Study 25923462 — intervention group
Group type: COMPARATOR
Intervention: Coronary heart disease (CHD) group
Number of subjects: 40
Study 23590407 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain model (hypertonic saline injection in infrapatellar fat pad)
Number of subjects: 17
Study 23590407 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline injection in contralateral infrapatellar fat pad)
Number of subjects: 17
Study 21256045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral (TF) approach
Number of subjects: 35
Study 21256045 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-apical (TA) approach
Number of subjects: 35
Study 21256045 — intervention group
Group type: COMPARATOR
Intervention: Conventional aortic valve surgery (AVR) control group
Number of subjects: 35
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 50
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaFlo DC
Number of subjects: 50
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II
Number of subjects: 50
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 50
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Core
Number of subjects: 50
Study 19583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement
Number of subjects: 50
Study 17357053 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug EFV regimen (zidovudine/lamivudine plus EFV)
Number of subjects: 64
Study 17357053 — intervention group
Group type: COMPARATOR
Intervention: Triple-nucleoside regimen (zidovudine/lamivudine/abacavir)
Number of subjects: 64
Study 17357053 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug EFV regimen (zidovudine/lamivudine/abacavir plus EFV)
Number of subjects: 64
Study 16859064 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/day)
Number of subjects: 0
Study 16859064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (5-100 mg/day)
Number of subjects: 0
Study 16859064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cardiac baroreceptor sensitivity (BRS) defined as BRS ≤ 5.0 ms/mm Hg
Number of subjects: 124
Study 12624295 — intervention group
Group type: COMPARATOR
Intervention: Normal cardiac baroreceptor sensitivity (BRS) defined as BRS > 5.0 ms/mm Hg
Number of subjects: 124
Study 12624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac BRS assessment using power spectral analysis techniques
Number of subjects: 124
Study 10849042 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan, 5 mg
Number of subjects: 56
Study 10849042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan, 10 mg
Number of subjects: 56
Study 10849042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both zolmitriptan and rizatriptan
Number of subjects: 56
Study 8656666 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril, 5 mg once daily
Number of subjects: 40
Study 8656666 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol, 100 mg once daily
Number of subjects: 40
Study 1877363 — intervention group
Group type: EXPERIMENTAL
Intervention: Small meal
Number of subjects: 4
Study 1877363 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 4
Study 1877363 — intervention group
Group type: COMPARATOR
Intervention: Both small and large meals
Number of subjects: 4
Study 6285721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5 percent acyclovir in polyethylene glycol
Number of subjects: 208
Study 6285721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 31487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention based on motivational interview (3 sessions of 40 min each over 6 weeks)
Number of subjects: 56
Study 31487444 — intervention group
Group type: COMPARATOR
Intervention: Conventional management of education (control group)
Number of subjects: 56
Study 27849389 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Number of subjects: 414
Study 27849389 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 414
Study 25117302 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GDF-15 levels in HD patients
Number of subjects: 87
Study 25117302 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GDF-15 levels
Number of subjects: 87
Study 25117302 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 as an independent variable
Number of subjects: 87
Study 25117302 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT assessment
Number of subjects: 87
Study 23696515 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-PDFF
Number of subjects: 50
Study 23696515 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS-PDFF
Number of subjects: 50
Study 23696515 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-PDFF and MRS-PDFF
Number of subjects: 50
Study 20925971 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or Olanzapine
Number of subjects: 628
Study 19323930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin (80 mg simvastatin for 7 days)
Number of subjects: 228
Study 17320304 — intervention group
Group type: EXPERIMENTAL
Intervention: School-wide no smoking strategy and six-session smoking prevention curriculum
Number of subjects: 469
Study 17320304 — intervention group
Group type: EXPERIMENTAL
Intervention: School-wide no smoking strategy
Number of subjects: 469
Study 17320304 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 469
Study 14744507 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11158043 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (0.5 mg) after esmolol pretreatment
Number of subjects: 18
Study 11158043 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (0.5 mg) after dobutamine pretreatment
Number of subjects: 18
Study 9576193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction and consolidation chemotherapy (4 courses)
Number of subjects: 359
Study 9576193 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplant (A-BMT)
Number of subjects: 359
Study 9576193 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplant (allo-BMT)
Number of subjects: 359
Study 9576193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 359
Study 9576193 — intervention group
Group type: COMPARATOR
Intervention: Thioguanine
Number of subjects: 359
Study 9576193 — intervention group
Group type: COMPARATOR
Intervention: Etoposide
Number of subjects: 359
Study 7889896 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-stay (LS) group, retained in hospital for full nutritional rehabilitation (mean 40 days)
Number of subjects: 81
Study 7889896 — intervention group
Group type: COMPARATOR
Intervention: Short-stay (SS) group, discharged immediately (mean 18 days) for standard Health Service care at home for 6 months plus high-energy supplement (3.31 MJ with 20.6 g protein daily) for first 3 months
Number of subjects: 81